131 related articles for article (PubMed ID: 27920815)
21. Renal papillary necrosis induced by naproxen.
Kovacevic L; Bernstein J; Valentini RP; Imam A; Gupta N; Mattoo TK
Pediatr Nephrol; 2003 Aug; 18(8):826-9. PubMed ID: 12774222
[TBL] [Abstract][Full Text] [Related]
22. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities.
Herlitz LC; Mohan S; Stokes MB; Radhakrishnan J; D'Agati VD; Markowitz GS
Kidney Int; 2010 Dec; 78(11):1171-7. PubMed ID: 20811330
[TBL] [Abstract][Full Text] [Related]
23. The outcome of delayed graft function in cadaveric renal transplants treated with low dose cyclosporine.
Chung YC; Lee PH; Hu RH; Chang CN; Chen CJ; Lee CS
J Formos Med Assoc; 1991 Oct; 90(10):975-80. PubMed ID: 1685180
[TBL] [Abstract][Full Text] [Related]
24. A Rare Presentation of Zoledronate-Induced Systemic Inflammatory Response.
Jamil M; Daneshvar A; Nachawati D; El Sharu H; Meysami A
Cureus; 2023 Jul; 15(7):e41524. PubMed ID: 37551226
[TBL] [Abstract][Full Text] [Related]
25. Renal recovery from acute tubular necrosis requiring renal replacement therapy: a prospective study in critically ill patients.
Schiffl H
Nephrol Dial Transplant; 2006 May; 21(5):1248-52. PubMed ID: 16449291
[TBL] [Abstract][Full Text] [Related]
26. Proximal Renal Tubular Acidosis Complicated by Severe Hypocalcemia Caused by Malnutrition and Inappropriate Long-term Use of Zoledronate: A Case Report and Review of the Literature.
Fujita N; Ono Y; Yamashita K; Kimata M; Sekizawa A; Hashimoto K; Obuchi Y; Tanaka Y
Intern Med; 2023 Dec; ():. PubMed ID: 38044157
[TBL] [Abstract][Full Text] [Related]
27. Characterization of urinary biomarkers and their relevant mechanisms of zoledronate-induced nephrotoxicity using rats and HK-2 cells.
Lan Z; Chai K; Jiang Y; Liu X
Hum Exp Toxicol; 2019 May; 38(5):598-609. PubMed ID: 30744404
[TBL] [Abstract][Full Text] [Related]
28. Adult-size kidneys without acute tubular necrosis provide exceedingly superior long-term graft outcomes for infants and small children: a single center and UNOS analysis. United Network for Organ Sharing.
Sarwal MM; Cecka JM; Millan MT; Salvatierra O
Transplantation; 2000 Dec; 70(12):1728-36. PubMed ID: 11152105
[TBL] [Abstract][Full Text] [Related]
29. Morphology of ischemic acute renal failure, normal function, and cyclosporine toxicity in cyclosporine-treated renal allograft recipients.
Solez K; Racusen LC; Marcussen N; Slatnik I; Keown P; Burdick JF; Olsen S
Kidney Int; 1993 May; 43(5):1058-67. PubMed ID: 8510383
[TBL] [Abstract][Full Text] [Related]
30. Acute bilateral uveitis and right macular edema induced by a single infusion of zoledronic acid for the treatment of postmenopausal osteoporosis as a substitution for oral alendronate: a case report.
Tian Y; Wang R; Liu L; Ma C; Lu Q; Yin F
BMC Musculoskelet Disord; 2016 Feb; 17():72. PubMed ID: 26867651
[TBL] [Abstract][Full Text] [Related]
31. Urinary interleukin-18 is a marker of human acute tubular necrosis.
Parikh CR; Jani A; Melnikov VY; Faubel S; Edelstein CL
Am J Kidney Dis; 2004 Mar; 43(3):405-14. PubMed ID: 14981598
[TBL] [Abstract][Full Text] [Related]
32. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.
Tan W; Sun J; Zhou L; Li Y; Wu X
J Clin Pharm Ther; 2016 Oct; 41(5):519-23. PubMed ID: 27440710
[TBL] [Abstract][Full Text] [Related]
33. Severe non-infective systemic inflammatory response syndrome, shock, and end-organ dysfunction after zoledronic acid administration in a child.
Trivedi S; Al-Nofal A; Kumar S; Tripathi S; Kahoud RJ; Tebben PJ
Osteoporos Int; 2016 Jul; 27(7):2379-2382. PubMed ID: 26892041
[TBL] [Abstract][Full Text] [Related]
34. Adefovir nephrotoxicity in a renal allograft recipient.
George N; Basu G; Mohapatra A; Zachariah U; Abraham P; Korula A; Varughese S; Jacob CK; Tamilarasi V
Indian J Nephrol; 2015; 25(3):180-3. PubMed ID: 26060371
[TBL] [Abstract][Full Text] [Related]
35. Current management strategies for hypercalcemia.
Pecherstorfer M; Brenner K; Zojer N
Treat Endocrinol; 2003; 2(4):273-92. PubMed ID: 15966562
[TBL] [Abstract][Full Text] [Related]
36. Once-yearly intravenous zoledronate does not impair renal function in postmenopausal women.
Lafage-Proust MH
Kidney Int; 2008 Sep; 74(5):557-9. PubMed ID: 18709026
[TBL] [Abstract][Full Text] [Related]
37. Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies.
Fervenza FC; Fitzpatrick PM; Mertz J; Erickson SB; Liggett S; Popham S; Wochos DN; Synhavsky A; Hippler S; Larson TS; Bagniewski SM; Velosa JA;
Nephrol Dial Transplant; 2004 May; 19(5):1288-92. PubMed ID: 15102967
[TBL] [Abstract][Full Text] [Related]
38. Zoledronate once-yearly increases bone mineral density--implications for osteoporosis.
Doggrell SA
Expert Opin Pharmacother; 2002 Jul; 3(7):1007-9. PubMed ID: 12083999
[TBL] [Abstract][Full Text] [Related]
39. Bmi-1 plays a critical role in the protection from acute tubular necrosis by mobilizing renal stem/progenitor cells.
Lv X; Yu Z; Xie C; Dai X; Li Q; Miao D; Jin J
Biochem Biophys Res Commun; 2017 Jan; 482(4):742-749. PubMed ID: 27871857
[TBL] [Abstract][Full Text] [Related]
40. Distinct effect of zoledronate and clodronate on circulating levels of DKK1 and sclerostin in women with postmenopausal osteoporosis.
Gatti D; Viapiana O; Idolazzi L; Fracassi E; Ionescu C; Dartizio C; Troplini S; Kunnathully V; Adami S; Rossini M
Bone; 2014 Oct; 67():189-92. PubMed ID: 25003812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
